Last edition
News about
US FDA approves Viridian's Lumvoa for treatment of thyroid eye disease
Viridian Therapeutics secures US FDA approval for Lumvoa, the first IGF-1R antagonist approved to treat both active and chronic thyroid eye disease, with commercial launch set to begin immediately.
Jubilant Generics Receives USFDA Tentative Approval for Pantoprazole Sodium Oral Suspension
FDA’s tentative approval strengthens Jubilant Generics' US product pipeline and positions the company to launch Pantoprazole Sodium Delayed Release Oral Suspension following patent expiry later this year.
Roche Launches AXELIOS 1 Sequencing Platform Powered by Proprietary SBX Technology
Roche’s AXELIOS 1, designed for research use, delivers rapid, accurate and scalable genomic sequencing, enabling researchers to accelerate discoveries across oncology, genetics, infectious diseases and other areas of biomedical research.
Alexion Reports Positive Phase 3 Results for Efzimfotase Alfa in Children with Rare Bone Disease
Alexion, AstraZeneca Rare Disease, has announced positive Phase 3 results for investigational enzyme replacement therapy efzimfotase alfa in children with HPP. The therapy demonstrated significant improvements in bone health and physical function, reinforcing its potential as a next-generation treatment for the rare inherited metabolic disorder.
Aurobindo Pharma USA Completes Acquisition of Lannett Company
Aurobindo Pharma USA has completed the acquisition of Lannett Company after securing approval from the US Federal Trade Commission. Effective June 29, 2026, Lannett will operate as Lannett Company LLC, with the combined entity aiming to strengthen the supply of essential medicines and enhance value for patients and customers.
Universe Pharmaceuticals to Acquire Patent Holding Firm in USD 10.75 Million Share Deal
Universe Pharmaceutical’s acquisition will strengthen Best Praise International's intellectual property portfolio with five China-based pharmaceutical patents, supporting its long-term strategy to expand research, product development and commercial opportunities in elderly healthcare and age-related diseases.
EMA Panel Recommends Revoking EU Authorisation for Tavneos Over Data Integrity Concerns
CHMP concludes pivotal clinical trial data cannot reliably demonstrate the drug’s efficacy, advises discontinuation for new patients and enhances liver monitoring for existing users.<br />
Alembic Pharmaceuticals Receives US FDA Approval for Dapsone Gel 5 Percent
Alembic Pharmaceuticals has received US FDA approval for Dapsone Gel 5 percent, a topical treatment for acne vulgaris.
Sobi Receives FDA Complete Response Letter for Experimental Gout Therapy NASP
Sobi has received a Complete Response Letter from the US FDA for its investigational gout therapy NASP, with the regulator requesting additional manufacturing data and facility-related information before considering approval. The company plans to work with the FDA and its manufacturing partners toward resubmitting the application.
Strides Pharma Science has sold a majority stake in its subsidiary, Pivot Path, to an Ascent Capital-led investor consortium for INR 100 crore, alongside a fresh INR 50 crore capital infusion that will support the company's expansion as an independent life sciences and digital transformation services provider.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy